What do we really know about metformin and ageing?
Metformin may extend healthy years by helping to prevent disease, but whether it also slows ageing itself in healthy people has not yet been proven. Wait for the TAME results before considering it as an anti-ageing drug, and weigh the side effects carefully.
Metformin reliably extends lifespan in the roundworm C. elegans, but that effect is fragile: change the bacterial strain or the glucose concentration, and the drug can actually shorten lifespan. Worm research rarely translates directly to humans, and this case illustrates why.
The strongest argument for metformin in ageing is not about living longer, but about preventing premature disease. Multiple studies suggest that the drug lowers the risk of diabetes, cardiovascular disease, cognitive decline and cancer. In that way it could extend the period spent in good health, even if lifespan extension in healthy people has not been demonstrated.
In cells and animal models, metformin acts on a range of ageing processes: damage to genetic material, shortening of the protective caps at chromosome ends (telomeres), and the senescence of cells that have stopped dividing but continue to harm surrounding tissue. Whether this also leads to a measurable slowing of the ageing process in humans has not yet been proven. A preliminary analysis of a smaller study showed changes in ageing-related gene activity, but that does not yet constitute evidence of a clinical effect.
The large TAME trial has been designed to test this directly in people without diabetes, but the results are not yet available. Meanwhile, a fundamental question lingers: after more than 60 years of clinical use, the exact mechanism of action of metformin is still not fully understood. Does it act directly on ageing processes, or does everything run through better blood sugar regulation?
Metformin also has drawbacks. Gastrointestinal complaints occur regularly, and long-term use can lower folate levels, a vitamin needed among other things for cell division and genetic material. There are also questions about effects on fertility with prolonged use. In addition, metformin barely breaks down in the environment: hormonal disruption has been observed in fish, which is an emerging concern.
Claims are based on a mix of pre-clinical research (cell studies, animal models, C. elegans), observational clinical data and an ongoing RCT (TAME). No definitive RCT results are available for the anti-ageing effect in people without diabetes.